Study finds weight loss drugs like Ozempic also improve liver health
Popular weight loss drugs such as Ozempic and Wegovy are also good for the liver, according to new research.
GLP-1 medicines improve liver health - regardless of weight loss, say scientists.
Canadian researchers found that semaglutide - the active ingredient in weight loss medications such as Ozempic and Wegovy that mimic the gut hormone GLP-1 - acts directly on a group of liver cells to improve organ function and does so independently of shedding weight.
Their findings, published in the journal Cell Metabolism, challenge long-held assumptions about how GLP-1 drugs work in the liver - and could reshape how doctors treat metabolic liver disease.
For years, the liver benefits of semaglutide puzzled scientists.
The drug was known to lower blood sugar and promote weight loss, but patients' livers were improving in ways that those effects alone could not explain.
Study lead author Dr. Daniel Drucker, of the Lunenfeld-Tanenbaum Research Institute, Toronto, said: "We've seen in clinical trials that patients who lose very little weight see the same reductions in liver inflammation, scarring and enzyme levels as those who lose a great deal of weight.
"Now we know why."
Drucker has been at the forefront of GLP-1 research since the 1980s when his pioneering discoveries helped lay the groundwork for the development of GLP-1 medicines.
After transforming treatment of Type 2 diabetes and obesity, semaglutide and other GLP-1 medicines have been approved for other conditions including metabolic dysfunction-associated steatohepatitis (MASH).
It is a severe form of fatty liver disease in which fat buildup, inflammation and tissue scarring can lead to cirrhosis and liver failure.
Drucker said MASH is closely linked with obesity and Type 2 diabetes, with treatment usually including lifestyle changes to reduce weight.
Now he and his colleagues have discovered that semaglutide acts directly on the liver to reduce inflammation and scarring and improve organ function in a way that is independent of weight loss.
Their findings overturn a prevailing assumption in the field that liver cells don't carry the receptor that semaglutide binds to, meaning the drug had no direct route to the organ.
Postdoctoral fellow Maria Gonzalez-Rellan spearheaded the work that combined sophisticated mouse models of MASH with deep molecular analysis of liver cells.
Her work identified two cell types carrying semaglutide receptors: liver sinusoidal endothelial cells (LSECs) and immune T cells.
Although LSECs account for only around 3% of liver cell volume, they proved to be the key driver of semaglutide's liver benefits.
Gonzalez-Rellan explained that LSECs line the tiniest blood vessels in the liver and are studded with pores that allow them to act as a molecular sieve, filtering substances passing between the liver and the bloodstream.
She showed that semaglutide reversed MASH in mice that lacked the brain receptors controlling appetite, demonstrating that weight loss is not required for liver benefits.
In another experiment, mice lacking LSEC receptors showed no liver improvement on semaglutide even after losing 20% of their body weight.
Detailed molecular analyses of liver cell types showed that semaglutide shifts gene activity in LSECs, prompting them to release anti-inflammatory molecules that act on the broader liver environment - pushing it toward a state more closely resembling a healthy, disease-free liver.
Drucker, who is also a professor of medicine at the University of Toronto, said: "It turns out that the receptor responsible for these benefits is in a very specialized population of liver cells.
"And this receptor orchestrates the production of molecules that talk to many different types of liver cells to calm down the inflammatory environment that is the problem in metabolic disease."
He says the findings carry practical implications.
GLP-1 medicines have become widely prescribed, yet their mechanism of action in the body, beyond appetite suppression and blood sugar control, remains not completely understood.
Drucker says knowing that semaglutide improves liver health independently of weight loss could influence prescribing decisions.
He said doctors may choose lower doses that avoid the side effects associated with the higher doses needed for significant weight loss, potentially also lowering costs for patients.
Drucker added: "We're not saying weight loss isn't important because many things improve when patients lose weight.
"But we now know that weight shouldn't be the only measure of success, because GLP-1 medicines will improve liver health whether or not the patient loses weight."
The post Study finds weight loss drugs like Ozempic also improve liver health appeared first on Talker.
Talker News
This story was originally published April 14, 2026 at 1:09 PM.